natgillin/translations-raw huggingface dataset:
Apixaban er en potent, oral, reversibel, direkte og yderst selektiv faktor Xa-hæmmer.
Apixaban is a potent, oral, reversible, direct and highly selective active site inhibitor of factor Xa.
Apixaban gav reduktion af apopleksi og systemisk emboli sammenlignet med warfarin på tværs af de forskellige niveauer af center TTI; for centre i den højeste kvartil af TTI var hazard ratio for apixaban versus warfarin 0,73 (95% CI, 0,38, 1,40).
Apixaban showed a reduction of stroke and systemic embolism compared to warfarin across the different levels of center TTR; within the highest quartile of TTR according to center, the hazard ratio for apixaban vs warfarin was 0.73 (95% CI, 0.38, 1.40).
Apixaban kan tages sammen med eller uden føde.
Apixaban can be taken with or without food.
Apixaban kan tages sammen med eller uden mad.
Apixaban can be taken with or without food.
Apixaban N = 2.798 n(%/år)
Apixaban N = 2,798 n(%/year)
Apixaban N = 2.807 n (%/år)
Apixaban N = 2,807 n (%/year)
Apixaban N = 9.088 n (%/år)
Apixaban N = 9,088 n (%/year)
Apixaban N=9.120 n (%/år)
Apixaban N=9,120 n (%/yr)
Apixabans farmakokinetik er tilnærmelsesvis lineær med dosis proportionale stigninger i eksponeringen til apixaban ved doser op til 10 mg.
Apixaban demonstrates linear pharmacokinetics with dose proportional increases in exposure for oral doses up to 10 mg.
Apixabans farmakokinetik er tilnærmelsesvis lineær med dosisproportionale stigninger i eksponeringen til apixaban ved doser op til 10 mg.
Apixaban demonstrates linear pharmacokinetics with dose proportional increases in exposure for oral doses up to 10 mg.
Apixabans virkning ved initial behandling af VTE var den samme blandt patienter, som blev behandlet for LE [relativ risiko 0,9; 95% CI (0,5-1,6)] eller DVT [relativ risiko 0,8; 95% CI (0,5-1,3)].
Apixaban efficacy in initial treatment of VTE was consistent between patients who were treated for a PE [Relative Risk 0.9; 95% CI (0.5, 1.6)] or DVT [Relative Risk 0.8; 95% CI (0.5, 1.3)].
APL er en unik type myeloid leukæmi, en sygdom, hvor der forekommer unormale hvide blodlegemer og unormal blødning og blå mærker.
APL is a unique type of myeloid leukaemia, a disease in which abnormal white blood cells and abnormal bleeding and bruising occur.
aPlacebokontrollerede kliniske studier (fase III), hvor patienter med moderat til svær plaque-psoriasis blev eksponeret for ixekizumab 80 mg Q2W, ixekizumab 80 mg Q4W eller placebo i en behandlingsperiode på op til 12 uger. bInfektion i øvre luftveje inkluderer nasofaryngitis og infektion i øvre luftveje. cOral candidiasis inkluderer de foretrukne termer oral candidiasis og oral svampeinfektion. dCellulitis inkluderer cellulitis forårsaget af stafylokokker og cellulitis i det ydre øre samt erysipelas. eReaktioner på injektionsstedet var hyppigere hos personer med legemsvægt < 60 kg sammenlignet med gruppen med legemsvægt ≥ 60 kg (25 % vs.
a Placebo-controlled clinical studies (phase III) in moderate to severe plaque psoriasis patients exposed to ixekizumab 80 mg Q2W, ixekizumab 80 mg Q4W or placebo for up to 12 weeks of treatment duration b Upper respiratory tract infection includes nasopharyngitis and upper respiratory tract infection c Oral candidiasis defined as events with the preferred terms oral candidiasis and oral fungal infection d Cellulitis includes staphylococcal and external ear cellulitis, and erysipelas e Injection site reactions were more common in subjects with a body weight < 60 kg compared with the group with a body weight ≥ 60 kg (25 % vs.
Aplasi med umodne røde blodlegemer (PRCA)*
Pure red cell aplasia (PRCA)
Aplasi, misdannelse i mave-tarm-kanalen, iktyose
Macrophage activation
Aplastik anæmi٭
Aplastic anaemia
aplastisk anæmi, ekkymose
aplastic anaemia, ecchymosis
aplastisk anæmi, pure red cell aplasi (en tilstand, hvor kroppen er ophørt med eller har nedsat produktionen af røde blodlegemer).
aplastic anaemia, pure red cell aplasia (a condition where the body stopped or reduced the
aplastisk anæmi, ren erytroaplasi (en tilstand hvor kroppen stoppede eller reducerede
aplastic anaemia, pure red cell aplasia (a condition where the body stopped or reduced the
Aplastisk anæmi٭
Aplastic anaemia
Apnø hos for tidligt fødte spædbørn skyldes, at barnets vejrtrækningscenter i hjernen ikke er fuldt udviklet.
Apnoea in premature babies is due to the baby’s breathing centres in the brain not being fully developed.
Apnø hos meget præmature spædbørn (≤ 28 ugers svangerskab) (se pkt.
Apnoea in very premature infants (≤ 28 weeks of gestation) (see section 4.4)
Apnø hos præmature spædbørn (≤ 28 gestationsuge) (se afsnit 4.4)
Apnoea in very premature infants (≤ 28 weeks of gestation) (see section 4.4)
Apnø Hoste Dyspnø Hikke
Apnoea Cough Dyspnoea Hiccups
Apnø#
Apnoea#
Apnø**, dyspnø**, laryngospasme**, respirationsstop**
Apnoea**, dyspnea**, laryngospasm**, respiratory arrest
Apo A1 (%)
ApoA1 (%)
Apo AI (g/l)
Fibrinogen* (g/L)
ApoB/ ApoA1- ratio
ApoB/ ApoA1 Ratio
Apolipoprotein B falder også væsentligt under behandling med simvastatin.
Apolipoprotein B also falls substantially during treatment with simvastatin.
Apopleksi
Cerebrovascular accident
Apopleksi
Stroke
Apopleksi
troke
Apopleksi (eksklusive apopleksi efter blokade af arterier).
Stroke (excluding apoplexy after the blockage of the arteries),
Apopleksi (utilstrækkelig blodtilførsel til hjernen, som kan medføre, at De ikke kan bevæge en eller flere lemmer på den ene side af kroppen, at De ikke kan forstå eller formulere tale eller ikke kan se den ene side af synsfeltet).
Stroke (insufficient blood supply to the brain, which may lead to inability to move one or more limbs on one side of the body, inability to understand or formulate speech, or an inability to see one side of the visual field).
Apopleksi eller systemisk emboli
Stroke or systemic embolism
Apopleksi eller systemisk emboli*
Stroke or systemic embolism
Apopleksi og systemisk non-CNS-emboli
Stroke and non-CNS systemic embolism
Apopleksi og transitorisk iskæmisk attak (TIA) i anamnesen.
Any history of stroke or transient ischaemic attack (TIA).
Apopleksi og/eller systemisk emboli
Stroke and/or SEE
Apopleksi optrådte hos 296 (7,8 %) af de patienter, der fik clopidogrel + ASA, og hos 408 (10,8 %) af de patienter, der fik placebo + ASA (relativ risikoreduktion 28,4 %; 95 % CI, 16,8% til 38,3%, p = 0,00001).
Strokes occurred in 296 (7.8%) patients receiving clopidogrel + ASA and 408 (10.8%) patients receiving placebo + ASA (relative risk reduction, 28.4%; 95% CI, 16.8% to 38.3%; p=0.00001).
Apopleksi optrådte hos 296 (7,8 %) af de patienter, der fik clopidogrel + ASA, og hos 408 (10,8 %) af de patienter, der fik placebo + ASA (relativ risikoreduktion 28,4 %; 95% CI, 16,8 % til 38,3 %, p = 0,00001).
Strokes occurred in 296 (7.8%) patients receiving clopidogrel + ASA and 408 (10.8%) patients receiving placebo + ASA (relative risk reduction, 28.4%; 95% CI, 16.8% to 38.3%; p=0.00001).
Apopleksi optrådte hos 296 (7,8%) af de patienter, der fik clopidogrel + ASA, og hos 408 (10,8%) af de patienter, der fik placebo + ASA (relativ risikoreduktion 28,4%; 95% CI, 16,8% til 38,3%, p = 0,00001).
Strokes occurred in 296 (7.8%) patients receiving clopidogrel + ASA and 408 (10.8%) patients receiving placebo + ASA (relative risk reduction, 28.4%; 95% CI, 16.8% to 38.3%; p=0.00001).
Apopleksi, systemisk emboli, MI eller vaskulær død*†
Stroke, systemic embolism, MI, or vascular death
Apopleksi, systemisk non-CNS-emboli og vaskulær død
Stroke, non-CNS systemic embolism and vascular death
Apopleksi, systemisk non-CNS-emboli, vaskulær død og myokardieinfarkt
Stroke, non-CNS systemic embolism, vascular death and myocardial infarction
Apopleksi1 (inklusive hjerneblødning) Synkope Transitorisk cerebral iskæmi1 Migræne2 Kramper Forbigående hukommelsestab
Stroke1 (including haemorrhagic events), Syncope, Transient ischaemic attacks1, Migraine2, Seizures, Transient amnesia
Apopleksi2 (inklusive hjerneblødning),
Stroke2 (including haemorrhagic events)
APOQUEL 16 mg tabletter
APOQUEL 16 mg tablets
APOQUEL 3,6 mg 3,6 mg oclacitinib (som oclacitinibmaleat) APOQUEL 5,4 mg 5,4 mg oclacitinib (som oclacitinibmaleat) APOQUEL 16 mg 16 mg oclacitinib (som oclacitinibmaleat)
APOQUEL 3.6 mg 3.6 mg oclacitinib (as oclacitinib maleate) APOQUEL 5.4 mg 5.4 mg oclacitinib (as oclacitinib maleate) APOQUEL 16 mg 16 mg oclacitinib (as oclacitinib maleate)
APOQUEL 3,6 mg filmovertrukne tabletter til hunde APOQUEL 5,4 mg filmovertrukne tabletter til hunde APOQUEL 16 mg filmovertrukne tabletter til hunde
APOQUEL 3.6 mg film-coated tablets for dogs APOQUEL 5.4 mg film-coated tablets for dogs APOQUEL 16 mg film-coated tablets for dogs
APOQUEL 3,6 mg tabletter
APOQUEL 3.6 mg tablets
APOQUEL 3,6 mg tabletter til hunde APOQUEL 5,4 mg tabletter til hunde APOQUEL 16 mg tabletter til hunde
APOQUEL 3.6 mg tablets for dogs APOQUEL 5.4 mg tablets for dogs APOQUEL 16 mg tablets for dogs
APOQUEL 5,4 mg tabletter
APOQUEL 5.4 mg tablets
Apoquel bør ikke gives til hunde med tegn på immunundertrykkelse eller fremadskridende kræft, da Apoquel ikke er undersøgt i sådanne tilfælde.
Apoquel should not be given to dogs with signs of immune suppression or progressive cancer as Apoquel has not been studied in such cases.
Apoquel bør ikke gives til hunde under ét år eller under 3 kg.
Apoquel should not be given to dogs less than one year of age or weighing less than 3 kg.
APOQUEL tabletter fås i blisterpakninger eller HDPE flaske med 20, 50 eller 100 tabletter pr. pakning.
APOQUEL tablets are supplied in either blister packs or bottles with 20, 50 or 100 tablets per pack.
Apotekeren eller sygeplejersken vil beregne den nøjagtige dosis, som du har brug for.
The pharmacist or nurse will calculate the exact dose you need.
Apotekerfremstilling foretrækkes frem for fremstilling hjemme, da apotekeren kan måle dosen mere nøjagtigt.
The solution made up by a pharmacist is preferable to a home preparation as a pharmacist can measure the dose more accurately.
Apoteket skal anvende afkrydsningslisten til apoteker
The pharmacist must make use of the checklist for pharmacist
Apoteket skal gøre brug af tjeklisten for farmaceuter.
The pharmacist must make use of the checklist for pharmacist
Apoteket skal informere patienterne om, at de skal opbevare PecFent næsespray på et sikkert sted, for at undgå tyveri og misbrug og diversion
The pharmacist must inform the patients that in order to prevent theft and misuse of PecFent nasal spray they have to keep it in a safe place to avoid misuse and diversion
Apoteket skal være bekendt med uddannelsesmaterialet for PecFent næsespray, før det bruges i systemet
The pharmacist must be familiar with the educational material of PecFent nasal spray before using it in his/her organization
Apoteket skal være introduceret til undervisningsmaterialet for Instanyl næsespray, inden det benyttes til patienter.
The pharmacist must be familiar with the educational material of Instanyl nasal spray before using it in his/her organisation.
Apoteket skal være opmærksom på, at off label ordinering og mistanke om misbrug af Instanyl skal rapporteret i henhold til lokale retningslinjer for bivirkningsrapportering.
The pharmacist should be aware that off label prescription and suspected abuse or misuse of Instanyl should be reported according to your local guidelines for adverse reactions reporting.
Apoteket skal, for at forebygge tyveri og misbrug af Instanyl næsespray, informere patienter om, at de skal opbevare næsesprayen et sikkert sted for at undgå misbrug og videresalg.
The pharmacist must inform the patients that in order to prevent theft and misuse of Instanyl nasal spray they have to keep it in a safe place to avoid misuse and diversion.
Apoteket vil bortskaffe medicinrester.
Do not throw away any medicines via wastewater or household waste.
Apoteket vil udlevere yderligere sprøjter, hvis der er behov for mere end én sprøjte om dagen.
Additional syringes are provided in case more than one syringe is needed per day.
Apotekets telefonnummer:
Pharmacist’s telephone:
Apoteketspersonalet vil skrive udløbsdatoen på flaskeetiketten i den sorte rubrik “Anv. senest”.
The pharmacist will write the date of expiration on the bottle label in the black box next to "Use before".
apoteksfremstilletDoser den apoteksopblandede suspension med en inddelt oral sprøjte, der kan måle små mængder suspension.
Dispense the pharmacy compounded suspension with a graduated oral syringe for measuring small amounts of suspension.
Apotekspersonalet eller sundhedspersonalet fortynder Noxafil koncentrat til infusionsvæske, opløsning, så koncentratet får den korrekte koncentration.
Noxafil concentrate for solution for infusion will be diluted to the correct concentration by your pharmacist or nurse.
Apotex Inc.
Apotex Polska Sp. z o.o.
Apparatet sørger for at:
The device will ensure that:
Appelsin-vaniljesmagsstof
Orange vanilla flavour
Appendicitis, stafylokokinfektion, diverticulitis, cellulitis, absces i abdominalvæggen
Appendicitis, staphyloccocal infection, diverticulitis, cellulitis, abdominal wall abscess
Appetens matrix (lokkemad) indeholder tetracyklin-biomarkør .
Palatable matrix (bait) containing a tetracycline biomarker
appetitforstyrrelsera, hyperurikæmi
appetite disturbancesa, hyperuricaemia
appetitlø shed
loss of appetite
appetitløshed
anorexia
Appetitløshed
Anorexia (loss of appetite)
Appetitløshed
Appetite lost
appetitløshed
loss of appetite
Appetitløshed
Loss of appetite (anorexia)
Appetitløshed
loss of appetite,
appetitløshed
Loss of appetite.
Appetitløshed
Paresthesia oral Breath odour
appetitløshed (anoreksi)
loss of appetite (anorexia)
appetitløshed (anoreksi),
loss of appetite (anorexia)
appetitløshed (anoreksi),
loss of appetite (anorexia),
Appetitløshed (anoreksi), synkebesvær
loss of appetite (anorexia), difficulty in swallowing
Appetitløshed (anoreksi).
Loss of appetite (anorexia).
appetitløshed eller nedsat appetit,
loss (anorexia) or decrease of appetite
appetitløshed eller vægttab
loss of appetite or weight loss
Appetitløshed eller øget appetit
Loss of appetite or increased appetite
appetitløshed eller øget appetit, madlede over for visse fødemidler
decreased or increased appetite, not wanting to eat some foods
appetitløshed feber, 38 °C eller derover
loss of appetite high temperature of 38°C or higher
appetitløshed hovedpine.
loss of appetite headache.
appetitløshed mørk urin.
loss of appetite dark-coloured urine.
appetitløshed svaghed
reduced appetite weakness
appetitløshed, diaré, kvalme og opkastning nedsatte mængder af visse blodlegemer - din læge vil jævnligt kontrollere dit blod for dette og træffe beslutning om, hvorvidt der kræves nogen behandling.
loss of appetite, diarrhoea, feeling or being sick (nausea or vomiting) reduced levels of certain blood cells – your doctor will regularly check your blood for this and decide if any treatment is required.
Appetitløshed, hypofosfatæmi, hypoalbuminæmi, hypomagnesiæmi, hyponatriæmi, hypokaliæmi, hyperkaliæmi, hypokalcæmi, hyperbilirubinæmi
decreased appetite, hypophosphataemia, hypoalbuminaemia, hypomagnesaemia, hyponatraemia, hypokalaemia, hyperkalaemia, hypocalcaemia, hyperbilirubinemia
appetitløshed, mavesmerter eller dårlig mave, luft i maven, mundtørhed, ændret smagsfornemmelse
loss of appetite, stomach pain or upset stomach, passing wind, dry mouth, changes in your taste
appetitløshed, misfarvning, en knude eller blå mærker injektionsstedet.
loss of appetite, discolouration, lump or brusing at the injection site.
Appetitløshed, stigning i mængden af kropsvæske, forstyrrelser i kroppens saltbalance, højt indhold af sukker i blodet, lavt indhold af calcium i blodet, forhøjet calcium i blodet, lavt indhold af magnesium i blodet, stigning i syreindholdet i blodet
Loss of appetite, increase in amount of body fluid, imbalance of salt in the body, high sugar level in the blood, low calcium level in the blood, increase calcium level in the blood, low magnesium level in the blood, increase in acid level in the blood
Appetitløshed, synkebesvær
loss of appetite (anorexia), difficulty in swallowing
Appetitløshed, vægttab
Loss of appetite, weight loss
appetitløshed, vægttab (især ved kombination med det antiepileptiske lægemiddel natriumvalproat);
loss of appetite, weight loss (especially when combined with the antiepileptic medicine sodium valproate);
appetitløshed, vægttab (sædvanligvis ubetydeligt),
loss of appetite, weight loss (usually insignificant),
Appetitløshed, vægttab eller smagsforstyrrelser.
Anorexia, weight loss or a disturbed sense of taste.
appetitløshed, vægttab, mavesmerte, tør hud, irritation, hårtab, kløe, muskelsmerter, muskelømhed, smerte i led og muskler, udslæt.
loss of appetite, loss of weight, stomach pain, dry skin, irritation, hair loss, itching, muscle pain, muscle aches, pain in joints and muscles, rash.
appetitløshed, vægttab, mavesmerte, tør hud, irritation, smerter eller rødme på injektionsstedet, hårtab, kløe, muskelsmerter, muskelømhed, smerte i led og muskler, udslæt.
loss of appetite, loss of weight, stomach pain, dry skin, irritation, hair loss, itching, muscle pain, muscle aches, pain in joints and muscles, rash.
appetitløshed, vægttab, mavesmerte, tør hud, irritation, smerter eller rødme på injektionsstedet, hårtab, kløe, muskelsmerter, muskelømhed, smerte i led og muskler, udslæt.
loss of appetite, loss of weight, stomach pain, dry skin, irritation, pain or redness at the site of injection, hair loss, itching, muscle pain, muscle aches, pain in joints and muscles, rash.
Appetitløshed, vægttab, ændret smagssans
Decreased appetite, weight loss, altered sense of taste
Appetitløshed, øget appetit
Decreased appetite, increased appetite
Appetitløshed, øget appetit
Loss of appetite, increased appetite
Appetitløshed.
Loss of appetite.
appetitløshed;
anorexia (loss of appetite)
appetitløshed;
anorexia (loss of appetite);
Appetitmangel
Anorexia
Appetitmangel
Appetite lost
appetitmangel
lack of appetite
appetitmangel
lack of appetite;
appetitmangel
loss of appetite
appetitmangel (0,8 % over for 1,5 %), dyslipidæmi (0,8 % over for 0,3 %)
anorexia (0.8% vs 1.5%), dyslipidaemia (0.8% vs 0.3%)
appetitmangel forhøjede leverenzymer; dette kan ses i blodprøver og kan være tegn på nedsat leverfunktion eller leverskader.
loss of appetite increase of liver enzymes; these can be seen in the results of blood tests and can be a sign of reduced function or damage of the liver.
Appetitmangel, vægttab
Loss of appetite, decreased weight
Appetitmangel; maveirritation; mavekramper; forstoppelse; gulsot (hvor hud og/eller det hvide i øjne bliver farvet gul); betændelse i bugspytkirtlen med stærke smerter i øvre maveregion, ofte forbundet med kvalme og opkastning; søvnproblemer; depression; sløret syn; mangel på hvide blodlegemer, som kan resultere i hyppige infektioner; feber; nedsat antal blodplader (blodlegemer, som er nødvendige for, at blodet kan størkne); nedsat antal af røde blodlegemer (blodmangel), som karakteriseres ved træthed, hovedpine, forpustethed ved motion, svimmelhed og bleghed; nyresygdom; lungeproblemer, inklusive lungebetændelse eller ophobning af væske i lungerne; øget følsomhed af huden for sol; årebetændelse; hudsygdom som karakteriseres ved afskalning af huden over hele kroppen; kutan lupus erythematosus, som ses i form af udslæt i ansigt, hals og hovedbund; allergiske reaktioner; svækkelse og muskelkramper; ændring i puls; nedsat blodtryk efter ændringer i kropsstilling; hævede spytkirtler; højt sukkerindhold i blodet; sukker i urinen; øgning i bestemte typer af fedt i blod; for meget urinsyre i blodet, hvilket kan medføre urinsyregigt.
Loss of appetite; stomach irritation; stomach cramps; constipation; jaundice (yellowing of the skin and/or whites of the eyes); inflammation of the pancreas characterised by severe upper stomach pain, often with nausea and vomiting; sleep disorders; depression; blurred vision; lack of white blood cells, which can result in frequent infections, fever; decrease in the number of platelets (a blood cell essential for the clotting of the blood), decreased number of red blood cells (anaemia) characterised by tiredness, headaches, being short of breath when exercising, dizziness and looking pale; kidney disease; lung problems including pneumonia or build-up of fluid in the lungs; increased sensitivity of the skin to the sun; inflammation of blood vessels; a skin disease characterized by the peeling of the skin all over the body; cutaneous lupus erythematosus, which is identified by a rash that may appear on the face, neck, and scalp; allergic reactions; weakness and muscle spasm; altered heart rate; reduced blood pressure after a change in body position; swelling of the salivary glands; high sugar levels in the blood; sugar in the urine; increases in some kinds of blood fat; high uric acid levels in the blood, which may cause gout.
Appetitmangel; maveirritation; mavekramper; forstoppelse; gulsot (hvor hud og/eller det hvide i øjne bliver gulfarvet); bugspytkirtelbetændelse, med stærke smerter i øvre maveregion, ofte forbundet med kvalme og opkastning; søvnproblemer; depression; sløret syn; mangel på hvide blodceller, som kan resultere i hyppige infektioner; feber; nedsat antal blodplader (blodceller, som er nødvendige for, at blodet kan størkne); nedsat antal af røde blodceller (blodmangel), som karakteriseres ved træthed, hovedpine, forpustethed ved motion, svimmelhed og bleghed; nyresygdom; lungeproblemer, inklusive lungebetændelse eller ophobning af væske i lungerne; øget følsomhed af huden for sol; årebetændelse; hudsygdom som karakteriseres ved afskalning af huden over hele kroppen; kutan lupus erythematosus, som ses i form af udslæt i ansigt, hals og hovedbund; allergiske reaktioner; svækkelse og muskelkramper; ændring i puls; nedsat blodtryk efter ændringer i kropsstilling; hævelse af spytkirtler; højt sukkerindhold i blodet; sukker i urinen; øgning i bestemte typer af fedt i blod; høj mængde urinsyre i blodet, som kan lede til urinsyregigt.
Loss of appetite; stomach irritation; stomach cramps; constipation; jaundice (yellowing of the skin and/or whites of the eyes); inflammation of the pancreas characterised by severe upper stomach pain, often with nausea and vomiting; sleep disorders; depression; blurred vision; lack of white blood cells, which can result in frequent infections, fever; decrease in the number of platelets (a blood cell essential for the clotting of the blood), decreased number of red blood cells (anaemia) characterised by tiredness, headaches, being short of breath when exercising, dizziness and looking pale; kidney disease; lung problems including pneumonia or build-up of fluid in the lungs; increased sensitivity of the skin to the sun; inflammation of blood vessels; a skin disease characterized by the peeling of the skin all over the body; cutaneous lupus erythematosus, which is identified by a rash that may appear on the face, neck, and scalp; allergic reactions; weakness and muscle spasm; altered heart rate; reduced blood pressure after a change in body position; swelling of the salivary glands; high sugar levels in the blood; sugar in the urine; increases in some kinds of blood fat; high uric acid levels in the blood, which may cause gout.